Live Analyst Rating Changes 54325 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/David Lebowitz
BMO

David Lebowitz

BMO Capital
Wall Street Analyst
★★☆☆☆
#2470
on 13Foresight · ranked by our own returns
46%
Success Rate
+14.1%
Average Return
22 of 48 calls profitable · +7.5% vs benchmark
S&P 500 (SPY)
🔒 3-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 46% of David Lebowitz's ratings turned a profit when each position was held for 1 year — averaging +14.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

18 Buy 10 Hold 0 Sell
David's Stock Coverage 34 ratings · 2026-11-05
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
EXEL
Exelixis
 Oct 30, 2026 HOLD Buy
-34.0% avg upside
34 analysts
$60.00
13.54% Downside
 +1.7% ·
ALNY
Alnylam Pharma
 Oct 27, 2026 BUY Strong Buy
+76.3% avg upside
53 analysts
$318.00
92.64% Upside
 -30.9% ·
IONS
Ionis Pharmaceuticals
 Oct 21, 2026 BUY Strong Buy
+74.1% avg upside
44 analysts
$66.00
51.56% Upside
 -6.8% ·
CATX
Perspective Therapeutics
 Oct 20, 2026 BUY Strong Buy
+759.3% avg upside
24 analysts
$11.00
856.52% Upside
 -65.6% ·
BCAX
Bicara Therapeutics Inc.
 Oct 07, 2026 BUY Strong Buy
+247.1% avg upside
16 analysts
$35.00
283.33% Upside
 -50.1% ·
BMRN
BioMarin Pharmaceutical
 Oct 06, 2026 BUY Strong Buy
+63.6% avg upside
52 analysts
$97.00
65.83% Upside
 -0.2% ·
PRME
Prime Medicine, Inc.
 Sep 24, 2026 BUY Strong Buy
+101.7% avg upside
18 analysts
$9.00
90.78% Upside
 +45.0% ·
ASND
Ascendis Pharma
 Sep 14, 2026 BUY Strong Buy
+12.3% avg upside
29 analysts
$319.00
27.03% Upside
 -4.5% ·
AKTS
Aktis Oncology, Inc.
 Aug 18, 2026 BUY Strong Buy
+104.0% avg upside
12 analysts
$37.00
132.26% Upside
 -36.3% ·
COGT
Cogent Biosciences
 Sep 04, 2025 BUY Strong Buy
+24.4% avg upside
26 analysts
$22.00
29.09% Downside
 +168.6% ·
ARWR
Arrowhead Pharmaceuticals
 Sep 03, 2025 HOLD Strong Buy
+26.6% avg upside
29 analysts
$17.00
71.63% Downside
 +211.1% ·
CYTK
Cytokinetics
 Sep 03, 2025 BUY Strong Buy
+43.4% avg upside
36 analysts
$84.00
33.43% Upside
 +47.9% ·
BBIO
BridgeBio Pharma
 Sep 01, 2025 BUY Strong Buy
+26.0% avg upside
36 analysts
$67.00
10.64% Downside
 +53.1% ·
CLDX
Celldex
 Aug 20, 2025 BUY Strong Buy
+42.9% avg upside
28 analysts
$48.00
59.40% Upside
 +91.2% ·
VKTX
Viking Therapeutics
 Aug 20, 2025 HOLD Strong Buy
+172.0% avg upside
31 analysts
$29.00
6.38% Upside
 +33.8% ·
MDGL
Madrigal Pharmaceuticals
 Aug 19, 2025 BUY Strong Buy
+20.2% avg upside
34 analysts
$505.00
17.30% Upside
 +42.3% ·
MIRM
Mirum Pharmaceuticals
 Aug 18, 2025 BUY Strong Buy
+48.1% avg upside
24 analysts
$89.00
4.79% Upside
 +51.3% ·
SDGR
Schrodinger
 Aug 15, 2025 HOLD Strong Buy
+7.1% avg upside
16 analysts
$20.00
26.26% Downside
 -9.2% ·
PLRX
Pliant Therapeutics
 Aug 11, 2025 HOLD Buy
+2494.5% avg upside
21 analysts
$1.70
97.90% Upside
 -39.4% ·
NTLA
Intellia Therapeutics
 Aug 08, 2025 HOLD Buy
+187.2% avg upside
39 analysts
$12.00
3.86% Downside
 +10.7% ·
INCY
Incyte
 Jul 30, 2025 BUY Buy
-5.9% avg upside
49 analysts
$103.00
14.44% Downside
 +58.6% ·
PTCT
PTC Therapeutics
 Feb 11, 2025 SELL Buy
+35.4% avg upside
29 analysts
$45.00
24.96% Downside
 -45.8% ·
AKBA
Akebia Therapeutics
 Nov 05, 2021 HOLD Strong Buy
+1184.8% avg upside
16 analysts
$2.75
289.18% Upside
 -90.8% ·
IRWD
Ironwood Pharma
 Oct 12, 2021 HOLD Buy
+239.4% avg upside
23 analysts
$14.00
299.91% Upside
 -26.8% ·
TECX
Tectonic Therapeutic
 Oct 12, 2021 BUY Strong Buy
+176.5% avg upside
24 analysts
$25.00
26.46% Upside
 -89.4% ·
SNDX
Syndax Pharmaceuticals
 Oct 12, 2021 HOLD Strong Buy
+155.4% avg upside
27 analysts
$21.00
53.90% Upside
 +35.3% ·
KPTI
Karyopharm Therapeutics
 Oct 12, 2021 BUY Strong Buy
+2682.1% avg upside
18 analysts
$27.00
3978.56% Upside
 -12.3% ·
IMRX
Immuneering
 Aug 24, 2021 HOLD Strong Buy
+379.3% avg upside
12 analysts
$39.00
941.36% Upside
 -76.2% ·
RYTM
Rhythm Pharmaceuticals
 Aug 03, 2021 BUY Strong Buy
+39.2% avg upside
23 analysts
$54.00
41.65% Downside
 +5.4% ·
ARQT
Arcutis Biotherapeutics
 Jul 16, 2021 BUY Strong Buy
+29.0% avg upside
15 analysts
$50.00
55.98% Upside
 -5.5% ·
MGNX
MacroGenics
 Apr 30, 2021 SELL Buy
+638.9% avg upside
25 analysts
$17.00
608.39% Upside
 +77.9% ·
NBRVF
Nabriva Therapeutics
 Dec 07, 2020 HOLD Buy
+13374900.0% avg upside
9 analysts
$20.00
19999899.91% Upside
 · ·
SRPT
Sarepta Therapeutics
 Oct 02, 2017 BUY Buy
+223.8% avg upside
50 analysts
$60.00
222.23% Upside
 +187.4% ·
VRTX
Vertex Pharmaceuticals
 Jan 09, 2015 HOLD Strong Buy
-20.5% avg upside
62 analysts
$126.00
77.41% Downside
 -9.4% ·
🔒 29 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
David Lebowitz — Frequently Asked Questions
How accurate are David Lebowitz's stock ratings?
Based on the calls 13Foresight could measure, about 44% of David's ratings were profitable over a one-year hold, with an average return of +13.8% per rating, or +7.1% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is David ranked on 13Foresight?
David Lebowitz is currently ranked #2470 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does David cover?
David most recently has ratings on EXEL, ALNY, IONS, CATX, BCAX, BMRN, PRME, ASND, AKTS, COGT, ARWR, CYTK and 22 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.